Concepedia

Wei‐Chun Hsu

WH

Statistics

Publications

10

Citations

652

H-Index

10

Active since

2016

Affiliations

Novartis (United States)(Current)

Cornell University

BC Cancer Agency

University of California, San Francisco

UCSF Helen Diller Family Comprehensive Cancer Center

Wei‐Chun Hsu is an author at Novartis (United States) specializing in medicine, oncology, and hormone receptor-positive breast cancer immunotherapy.

Publications per year

2016–2024

10

Publications

10

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2021 · 349 citations

Medicine, Oncology, Pharmacology +17

Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer

Joshua A. Halpern, Art Sedrakyan, Wei‐Chun Hsu et al. · Cancer · 2016 · 80 citations · Full text

Medicine, Oncology, Radiation Oncology +14

90-day Readmission After Lumbar Spinal Fusion Surgery in New York State Between 2005 and 2014

Ali A. Baaj, Gernot Lang, Wei‐Chun Hsu et al. · Spine · 2017 · 41 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +15

Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, <i>PIK3CA</i>-Mutated Breast Cancer

Stuart Turner, Stephen Chia, Hemanth Kanakamedala et al. · The Oncologist · 2021 · 38 citations · Full text

Medicine, Oncology, Pharmacology +14

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2024 · 38 citations

Medicine, Oncology, Pharmacology +17

1–5 of 10